Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03801148 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT03801148 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 122 participants.
The verdict
NCT03801148, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg dexlansoprazole manufactured at TPC (Takeda Pharmaceutical Company Ltd.).
Interventions
- DRUG 30 mg dexlansoprazole capsules manufactured at TOB
- DRUG 30 mg dexlansoprazole capsules manufactured at TPC
- DRUG 60 mg dexlansoprazole capsules manufactured at TOB
- DRUG 60 mg dexlansoprazole capsules manufactured at TPC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2019-01-10 |
| Est. Completion | 2019-04-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03801148
The ClinicalTrials.gov registry entry for NCT03801148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 30 mg dexlansoprazole capsules manufactured at TOB is the first listed.
NCT03801148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03801148 about?
NCT03801148 is a clinical study titled "A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules". The purpose of this study is to assess the BA of 30 or 60 milligram (mg) dexlansoprazole capsule manufactured at TOB (Takeda GmbH Plant Oranienburg) to the corresponding 30 or 60 mg dexlansoprazole manufactured at TPC (Takeda Pharmaceutical Company Ltd.).
What is the current status of trial NCT03801148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2019-01-10. Estimated completion is 2019-04-09.
What interventions are being tested in trial NCT03801148?
The interventions under investigation include: 30 mg dexlansoprazole capsules manufactured at TOB (DRUG), 30 mg dexlansoprazole capsules manufactured at TPC (DRUG), 60 mg dexlansoprazole capsules manufactured at TOB (DRUG), 60 mg dexlansoprazole capsules manufactured at TPC (DRUG).
Who is sponsoring clinical trial NCT03801148?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.